Literature DB >> 22113844

Duration of time on intensive insulin therapy predicts severe hypoglycemia in the surgically critically ill population.

Nathan T Mowery1, Oliver L Gunter, Rondi M Kauffmann, Jose J Diaz, Bryan C Collier, Addison K May.   

Abstract

BACKGROUND: Hypoglycemia has emerged as a barrier to the practice of intensive insulin therapy. Current literature suggests that hypoglycemia occurs at variable rates and has different effects on outcomes in surgical and medical populations. We sought to determine the incidence, independent predictors, and effect on outcome of severe hypoglycemia (≤ 40 mg/dl) in a surgical population.
METHODS: A retrospective analysis was performed on all critically ill surgical patients treated with IIT from October 2004 to February 2007. Euglycemia (goal 80-110 mg/dl) was maintained using automated computerized titration of an insulin infusion. The primary outcome of interest was any episode of severe hypoglycemia (≤ 40 mg/dl). Multivariate logistic regression was used to determine the independent predictors of developing severe hypoglycemia.
RESULTS: A total of 60,298 data entries (1,118 patients) for glucose were analyzed. There were 64 severe hypoglycemic episodes in 52 patients (4.6% of the patients). There was a significant increase in deaths among patients who experienced at least one episode of hypoglycemia when compared with those who did not (26.9% vs. 15.3%, P = 0.03). Logistic regression revealed that the time spent on the protocol was the best predictor of developing a hypoglycemic event when controlling for other known risk factors of hypoglycemia.
CONCLUSIONS: Intensive insulin therapy can be implemented with a low percentage of patients (4.6%) experiencing severe hypoglycemia. Mortality rate was higher for patients experiencing hypoglycemia. The duration of the time spent on the protocol was the best predictor of hypoglycemia, suggesting that hypoglycemia is a mathematic probability of prolonged illness, not a reflection of illness severity or demographic features.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22113844     DOI: 10.1007/s00268-011-1356-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  42 in total

1.  A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes.

Authors:  K Foo; J Cooper; A Deaner; C Knight; A Suliman; K Ranjadayalan; A D Timmis
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

2.  Correlation between hyperglycemia and mortality in a medical and surgical intensive care unit.

Authors:  V Gabbanelli; S Pantanetti; A Donati; T Principi; P Pelaia
Journal:  Minerva Anestesiol       Date:  2005-11       Impact factor: 3.051

3.  Predisposing factors for hypoglycemia in the intensive care unit.

Authors:  Titia M Vriesendorp; Susanne van Santen; J Hans DeVries; Evert de Jonge; Frits R Rosendaal; Marcus J Schultz; Joost B L Hoekstra
Journal:  Crit Care Med       Date:  2006-01       Impact factor: 7.598

Review 4.  Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target?

Authors:  Greet Van den Berghe; Miet Schetz; Dirk Vlasselaers; Greet Hermans; Alexander Wilmer; Roger Bouillon; Dieter Mesotten
Journal:  J Clin Endocrinol Metab       Date:  2009-06-16       Impact factor: 5.958

Review 5.  Nutritional support.

Authors:  W W Souba
Journal:  N Engl J Med       Date:  1997-01-02       Impact factor: 91.245

Review 6.  The role of hyperglycemia in acute stroke.

Authors:  N Kagansky; S Levy; H Knobler
Journal:  Arch Neurol       Date:  2001-08

Review 7.  Critique of normoglycemia in intensive care evaluation: survival using glucose algorithm regulation (NICE-SUGAR)--a review of recent literature.

Authors:  Corey Scurlock; Jayashree Raikhelkar; Jeffrey I Mechanick
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-03       Impact factor: 4.294

8.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.

Authors:  Anthony P Furnary; Guangqiang Gao; Gary L Grunkemeier; YingXing Wu; Kathryn J Zerr; Stephen O Bookin; H Storm Floten; Albert Starr
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

9.  Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

Authors:  Renda Soylemez Wiener; Daniel C Wiener; Robin J Larson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

Review 10.  Insulin therapy for the critically ill patient.

Authors:  Greet Van den Berghe
Journal:  Clin Cornerstone       Date:  2003
View more
  5 in total

1.  Provision of balanced nutrition protects against hypoglycemia in the critically ill surgical patient.

Authors:  Rondi M Kauffmann; Rachel M Hayes; Judith M Jenkins; Patrick R Norris; Jose J Diaz; Addison K May; Bryan R Collier
Journal:  JPEN J Parenter Enteral Nutr       Date:  2011-07-12       Impact factor: 4.016

2.  Glycemia management in critical care patients.

Authors:  Federico Bilotta; Giovanni Rosa
Journal:  World J Diabetes       Date:  2012-07-15

3.  Hypocaloric enteral nutrition protects against hypoglycemia associated with intensive insulin therapy better than intravenous dextrose.

Authors:  Rondi M Kauffmann; Rachel M Hayes; Amanda H VanLaeken; Patrick R Norris; Jose J Diaz; Addison K May; Bryan R Collier
Journal:  Am Surg       Date:  2014-11       Impact factor: 0.688

Review 4.  Blood glucose measurement in the intensive care unit: what is the best method?

Authors:  Huong T Le; Neil S Harris; Abby J Estilong; Arvid Olson; Mark J Rice
Journal:  J Diabetes Sci Technol       Date:  2013-03-01

5.  Intravenous insulin therapy during lung resection does not affect lung function or surfactant proteins.

Authors:  Zdenek Ručka; Irena Koutná; Lenka Tesařová; Michaela Potěšilová; Stanislav Stejskal; Pavel Simara; Petr Vaňhara; Jan DoleŽel; Vaclav Zvoníček; Oldřich Coufal; Ivan Capov
Journal:  BMC Pulm Med       Date:  2014-10-02       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.